ESTRO 2024 - Abstract Book

S1713

Clinical - Lung

ESTRO 2024

Keywords: Brain metastases, SRS, WBRT

2073

Digital Poster

Outcomes following SABR for early-stage NSCLC in patients with interstitial lung disease (ILD)

David Quigley 1 , David Johnston 1 , Cathryn Crockett 1 , Jolyne O'Hare 1 , Linda Young 1 , Karen Tumelty 1 , Gerard G Hanna 1,2 , Jonathan McAleese 1,2 1 Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, Belfast, United Kingdom. 2 Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom

Purpose/Objective:

Interstitial lung disease (ILD) is relatively common in patients with primary lung cancer. Historically, radiotherapy was contraindicated in significant ILD due to concerns about toxicity. ILD is known to increase the risk of pulmonary complications and death after radical surgery and conventional radiotherapy. The aim of this study was to evaluate the outcomes of patients with ILD and early-stage (ES) non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SABR).

Material/Methods:

This retrospective, single-centre study reviewed all patients treated with SABR for ES NSCLC in a regional cancer centre between 2011-2022. A diagnosis of ILD was defined as being confirmed by a respiratory clinician or defined on diagnostic radiology. An exacerbation of ILD was defined as an admission with dyspnoea and ground glass nodules.

Results:

Twenty patients had a diagnosis of ILD, and 520 did not. Baseline demographics in the two groups were similar. The majority (65%) of those with ILD were treated with 50 Gy in 5 fractions. Higher doses were used in those without ILD (most frequently 55 Gy in 5fractions; 61%).At 1 year post treatment, patients treated with ILD had a non-significant increase in long term oxygen (LTOT) usage than those who did not have ILD (31% versus 4%, HR 0.54, 95% CI -0.10 2.84). An exacerbation of ILD was seen in 35% of the ILD cohort. There was no significant difference in overall survival or loco-regional control between ILD and non-ILD cohorts, with a median overall survival of 27 months for those with ILD versus 49 months for patients without ILD (HR 0.7 0.3 to 1.4).